ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Preoperative dual-ROI mpMRI radiomics integrating intratumoral and periprostatic adipose tissue features with clinical factors for predicting positive surgical margins after radical prostatectomy.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a preoperative mpMRI-based radiomics-clinical nomogram integrating dual-region radiomics features from intratumoral lesions and periprostatic adipose tissue (PPAT) with clinical factors for predicting positive surgical margins (PSM) after radical prostatectomy (RP) in non-metastatic prostate cancer (PCa). MATERIALS AND
methodsThis two-center retrospective study included 423 patients (age, 69.78 ± 6.30 years) with non-metastatic PCa who underwent mpMRI followed by RP between January 2019 and December 2024. Intratumoral and PPAT ROIs were manually segmented on T2-weighted images and apparent diffusion coefficient (ADC) maps. After reproducibility filtering, high-correlation removal, and least absolute shrinkage and selection operator (LASSO) regression, three radiomics signatures were constructed. Independent predictors were identified by multivariable logistic regression and integrated into a radiomics-clinical nomogram. Performance was assessed using ROC/AUC, FDR-adjusted DeLong tests, calibration curves, Hosmer-Lemeshow tests, decision curve analysis (DCA), and 1,000-iteration bootstrap validation; subgroup ROC analyses were also performed.
resultsTwelve intratumoral and nine PPAT radiomics features were selected, and the combined tumor-PPAT radiomics signature (TPR signature) demonstrated superior predictive performance compared with either single-ROI signature across cohorts (training AUC = 0.824; 95% CI, 0.776-0.865; validation AUC = 0.816; 95% CI, 0.737-0.935). Independent predictors included initial PSA, biopsy ISUP grade group, clinical T stage, and the TPR signature. The radiomics-clinical nomogram showed strong discrimination (AUC = 0.908 and 0.885 in the training and validation cohorts, respectively), with good calibration (Hosmer-Lemeshow p = 0.848 and 0.782) and favorable decision-curve performance across threshold probabilities of 0.1-1.0. Bootstrap resampling confirmed model stability, yielding mean AUCs of 0.908 (95% CI, 0.871-0.939) in the training cohort and 0.888 (95% CI, 0.827-0.936) in the validation cohort.
conclusionsA dual-ROI mpMRI radiomics-clinical nomogram integrating intratumoral and PPAT phenotypes enables accurate preoperative prediction of PSM after RP and may aid individualized surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.